Background Adult-onset Still’s disease (AOSD) is a systemic autoinflammatory disorder lacking a gold-standard diagnostic ...

That admission is what some in the field call recursive self-improvement (RSI), the point at which large language models ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals has been trying to rebuild momentum after a steep five year decline in shareholder returns, yet its ...

Nous Research has released Hermes Mixture of Agents 2.0 (MoA 2.0), an update to its open-source Hermes Agent framework that ...

Vitalik Buterin has published an updated long-term roadmap for Ethereum, calling the multi-year effort "Lean Ethereum" as the network's biggest redesign since ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

It's an upgrade worth making, but it comes down to your privacy concerns.

Mirendil, founded by two ex-Anthropic researchers, raised $200M at a $1bn valuation to sell self-improving AI research to everyone.

Spread the love“`html Artificial Intelligence (AI) has transcended its traditional role as a tool for human usage, evolving into a powerful force capable of creating and improving itself. This ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...